Innovation

Strolll® AR

2025 | Barri Morgan-Jones

Strolll® is a pioneering augmented reality (AR) digital therapeutic designed to transform neurological rehabilitation for Parkinson’s, stroke, and multiple sclerosis (MS). By integrating cutting-edge AR technology with evidence-based rehabilitation techniques, Strolll enhances mobility, balance, and engagement, making therapy more effective and accessible. With strong clinical validation, regulatory approvals, and seamless NHS integration, Strolll empowers healthcare providers to deliver data-driven, personalised rehabilitation that improves patient outcomes while offering cost-saving efficiencies to healthcare systems.

Strolll® is revolutionising neurological rehabilitation through augmented reality (AR)-driven digital therapeutics, providing an innovative, engaging, and data-driven approach to therapy. Designed for Parkinson’s, stroke, and multiple sclerosis (MS) patients, Strolll’s technology enhances gait, mobility, and motor function while addressing key rehabilitation challenges such as adherence and accessibility.

The platform integrates seamlessly into NHS and private healthcare settings, offering clinician-led, at-home, or hybrid therapy models. Strolll’s UKCA-approved solution for Parkinson’s is backed by real-world clinical evidence, including feasibility studies conducted with Leeds Teaching Hospitals, University of Leeds, Torbay & South Devon NHS Trust, and VU University Amsterdam. A £2.4 million i4i NIHR-funded clinical trial is currently underway, further validating its impact on patient outcomes and healthcare efficiencies.

Strolll is built to meet the highest standards of compliance and governance, ensuring DTAC readiness, DCB0129 compliance, and alignment with NHS digital frameworks. The platform offers cash-releasing and non-cash-releasing benefits, reducing hospital admissions, optimising clinician time, and improving rehabilitation access.

Beyond clinical validation, Strolll is expanding its capabilities, including a £1.3 million Randomised Controlled Trial (RCT) for stroke rehabilitation in the Netherlands and future UKCA approvals for stroke and MS rehabilitation.

By combining clinical expertise, immersive technology, and scalable implementation, Strolll is redefining digital therapeutics, making neurological rehabilitation more effective, engaging, and cost-efficient for healthcare systems worldwide.